Organon & Co. (OGN) is a global healthcare company that specializes in women's health, biosimilars, and established brands 1 6. The company was formed as a spin-off from Merck & Co. and launched as an independent, publicly traded entity on June 3, 2021 2 7.
Company OverviewOrganon's business is divided into three main segments:
- Women's Health: Focuses on contraception and fertility products, including Nexplanon and NuvaRing 1.
- Biosimilars: Develops and markets treatments for oncology and immunology 1.
- Established Brands: Offers over 60 medicines across various therapeutic areas 1.
Financial PositionDebt and Leverage:
- Organon's debt is significant, with a debt-to-EBITDA ratio of 5.0 3.
- The company aims to bring its net debt-to-EBITDA ratio below four by the end of 2024 5.
Assets:
- As of 2023, Organon reported:
- Total assets of $12.06 billion
- Tangible assets of $1.18 billion
- Intangible assets of $5.14 billion
- Cash and equivalents of $693 million 4
Cash Flow:
- The company generates strong cash flow, which supports its dividend and debt reduction efforts 5.
- Exact free cash flow (FCF) figures were not provided in the search results.
- Strategic Outlook Organon's CEO, Kevin Ali, expresses confidence in the company's ability to manage its debt and maintain its current dividend, citing strong cash flow generation and healthy EBITDA 5. The company's recent stock price momentum suggests that it may be moving past the challenging initial stage of the spin-off 5.
Despite its high debt levels, Organon expects lower interest expenses in 2024 due to reduced debt balances 5. The company offers an attractive dividend yield of over 5%, which is supported by its cash flow and represents a low 26% dividend payout ratio 5. |
